Glioblastoma, Adult
20
3
6
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
2 terminated out of 20 trials
83.3%
-3.2% vs benchmark
5%
1 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (20)
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
CSF Proteomic Characterization of Glioblastomas
Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas
Function and Composition of Regulatory B Cells in Participants With Glioblastoma
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
NCT Neuro Master Match - N²M² (NOA-20)
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
Ketogenic Diets as an Adjuvant Therapy in Glioblastoma